<DOC>
	<DOC>NCT00325260</DOC>
	<brief_summary>In the study Influvac will be compared to Agrippal, another subunit influenza vaccine that is already on the market in China. The main objective of the study is to show that both vaccines are comparable with regard to efficacy. In addition, safety and efficacy data with Influvac will be assessed in the Chinese population.</brief_summary>
	<brief_title>Non-Inferiority Study Comparing the Subunit Vaccines Influvac and Agrippal in China</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>signed and dated informed consent being healthy mental health enough to understand the study, the informed consent form and the questionnaire known to be allergic to constituents of the vaccine having an autoimmune disorder, taking immunomodulating drugs or having immune disfunction secondary to HIV having had a documented serious adverse reaction to previous influenza vaccination having had documented influenza infection or vaccination in the six months prior to the start of the study having received any other vaccines, immunoglobulins or investigational drugs in the month prior to the start of the study</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>influenza</keyword>
	<keyword>non-inferiority</keyword>
	<keyword>Influvac</keyword>
	<keyword>Agrippal</keyword>
	<keyword>healthy subjects</keyword>
</DOC>